106 related articles for article (PubMed ID: 16166962)
1. Novel endpoints in phase III clinical trials.
Sargent DJ
Clin Adv Hematol Oncol; 2005 Jan; 3(1):21-3. PubMed ID: 16166962
[No Abstract] [Full Text] [Related]
2. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
3. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
4. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Markman M
Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
[No Abstract] [Full Text] [Related]
5. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
7. [Validation of surrogate endpoints in digestive oncology].
Methy N; Bedenne L; Bonnetain F
Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
[TBL] [Abstract][Full Text] [Related]
8. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
Patsner B
Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
[No Abstract] [Full Text] [Related]
9. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
10. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
11. Applying sensitivity analyses to overall survival in cancer clinical trials.
Wolff SN
J Clin Oncol; 2010 Jul; 28(19):e323; author reply e324. PubMed ID: 20516448
[No Abstract] [Full Text] [Related]
12. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
13. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.
Glynne-Jones R; Mawdsley S; Novell JR
Colorectal Dis; 2006 Nov; 8(9):800-7. PubMed ID: 17032329
[TBL] [Abstract][Full Text] [Related]
14. Response rate as an endpoint in clinical trials.
George SL
J Natl Cancer Inst; 2007 Jan; 99(2):98-9. PubMed ID: 17227987
[No Abstract] [Full Text] [Related]
15. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
16. Statistics in oncology.
Land SR; Abrams J; Buyse M; Chappell RJ
J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
[No Abstract] [Full Text] [Related]
17. Quality-of-life outcomes in oncology.
Siddiqui F; Kachnic LA; Movsas B
Hematol Oncol Clin North Am; 2006 Feb; 20(1):165-85. PubMed ID: 16580562
[TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
Zia MI; Siu LL; Pond GR; Chen EX
J Clin Oncol; 2005 Oct; 23(28):6982-91. PubMed ID: 16192585
[TBL] [Abstract][Full Text] [Related]
19. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Eickhoff JC
Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
[TBL] [Abstract][Full Text] [Related]
20. Other endpoints in screening studies for soft tissue sarcomas.
Verweij J
Oncologist; 2008; 13 Suppl 2():27-31. PubMed ID: 18434636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
